Drug Profile


Alternative Names: CD4 Antigens; CD4 Immunoadhesin; Hybrid CD4; Recombinant CD4 Immunoglobulin G; Recombinant human CD4 Immunoglobulin G; Recombinant soluble CD4 Immunoglobulin G; rsCD4 IgG

Latest Information Update: 12 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections; Immune thrombocytopenic purpura

Most Recent Events

  • 28 Oct 2005 Discontinued - Phase-I for HIV-associated Immune thrombocytopenic purpura in USA (IV)
  • 28 Oct 2005 Discontinued-I for HIV infections in USA (IV)
  • 02 Nov 1999 Phase-I clinical trials in HIV-associated Immune thrombocytopenic purpura in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top